Company news

Veracyte, Inc. news in 2023

Veracyte, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 11, 2023

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

November 30, 2023

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

November 28, 2023

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

November 21, 2023

Veracyte Announces Third Quarter 2023 Financial Results

November 6, 2023

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

November 6, 2023

Veracyte to Participate in the Stephens Annual Investment Conference

November 1, 2023

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

October 26, 2023

Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023

October 16, 2023

New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease

October 11, 2023

New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier

October 3, 2023

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023

September 27, 2023

New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer

September 27, 2023

Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

September 26, 2023

Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

September 20, 2023

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests

September 6, 2023

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

September 5, 2023

Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 28, 2023

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

August 21, 2023

Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego

August 14, 2023

Veracyte Announces Second Quarter 2023 Financial Results

August 7, 2023

Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment

July 31, 2023

Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023

July 18, 2023

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

June 19, 2023

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

June 11, 2023

New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer

May 24, 2023

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

May 23, 2023

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

May 11, 2023

Veracyte Announces First Quarter 2023 Financial Results

May 3, 2023

New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules

May 3, 2023

Veracyte Announces Release of Inaugural ESG Report

May 2, 2023

New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients

May 2, 2023

Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer

May 1, 2023

Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

April 30, 2023

Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

April 28, 2023

Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting

April 26, 2023

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

April 16, 2023

Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023

April 12, 2023

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

April 11, 2023

Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners

March 14, 2023

Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank

March 10, 2023

Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results

February 21, 2023

Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

February 14, 2023

New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment

February 12, 2023

Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023

February 5, 2023

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

January 31, 2023

Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

January 31, 2023

Calls in 2023

Decks in 2023